| 翻訳と辞書 |
Tesofensine
Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity.〔 Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.〔(【引用サイトリンク】title=NeuroSearch A/S signs agreement to transfer Phase I-II projects NS2359 and NS2330 (Tesofensine) )〕
== History ==
Tesofensine was originally investigated for the treatment of Alzheimer's disease and Parkinson's disease,〔 and was subsequently dropped from development for these applications after early trial results showed limited efficacy for treatment of these diseases.〔〔 However, weight loss was consistently reported as an adverse event in the original studies, especially in overweight or obese patients.〔 Therefore, it was decided to pursue development of tesofensine for the treatment of obesity.
Tesofensine primarily acts as an appetite suppressant, but possibly also acts by increasing resting energy expenditure.〔 Phase 2 trials for the treatment of obesity have been successfully completed.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Tesofensine」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|